Physician profile
William Krotz
NPI 1194756452
$1,561.70
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $226 · 2021: $354 · 2022: $559.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $341.26 | 2019-2022 | |
| Pfizer INC. | $178.50 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $173.41 | 2019-2022 | |
| Abbott Laboratories | $162.48 | 2021-2022 | |
| Novo Nordisk INC | $121.99 | 2019-2022 | |
| Indivior INC. | $93.19 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.69 | 2019 | |
| Lilly USA, LLC | $65.68 | 2022 | |
| Dynavax Technologies Corporation | $61.07 | 2019-2022 | |
| Amarin Pharma, INC. | $55.47 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $42.30 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $41.39 | 2020 | |
| Mdd US Operations, LLC | $38.65 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.57 | 2019 | |
| Edwards Lifesciences Corporation | $26.23 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18.04 | 2022 | |
| Gilead Sciences, INC. | $13.43 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.35 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Krotz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.